Last reviewed · How we verify
Comparator: Placebo to efavirenz
Comparator: Placebo to efavirenz is a Non-nucleoside reverse transcriptase inhibitor (NNRTI) Small molecule drug developed by Merck Sharp & Dohme LLC. It is currently in Phase 3 development for HIV-1 infection (as part of combination antiretroviral therapy).
Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that blocks HIV reverse transcriptase to prevent viral replication.
Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that blocks HIV reverse transcriptase to prevent viral replication. Used for HIV-1 infection (as part of combination antiretroviral therapy).
At a glance
| Generic name | Comparator: Placebo to efavirenz |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | Non-nucleoside reverse transcriptase inhibitor (NNRTI) |
| Target | HIV reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | Phase 3 |
Mechanism of action
Efavirenz binds directly to HIV reverse transcriptase and inhibits its enzymatic activity, preventing the conversion of viral RNA into DNA and thus blocking HIV replication. It is used as part of combination antiretroviral therapy (ART) to suppress viral load in HIV-infected patients. The drug crosses the blood-brain barrier effectively, making it useful for treating CNS HIV infection.
Approved indications
- HIV-1 infection (as part of combination antiretroviral therapy)
Common side effects
- Dizziness
- Rash
- Nausea
- Headache
- Insomnia
- Impaired concentration
- Elevated liver enzymes
Key clinical trials
- Comparison of Doravirine, Tenofovir, Lamivudine (MK-1439A) and ATRIPLA™ in Treatment-Naive Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Participants (MK-1439A-021) (PHASE3)
- A Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 Versus Efavirenz in Treatment Naive HIV-Infected Patients, Each in Combination With TRUVADA (0518-021 EXT) (PHASE3)
- A Study to Evaluate the Safety and Efficacy of an Investigational Drug in HIV Infected Patients (0518-004)(COMPLETED) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Comparator: Placebo to efavirenz CI brief — competitive landscape report
- Comparator: Placebo to efavirenz updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI
Frequently asked questions about Comparator: Placebo to efavirenz
What is Comparator: Placebo to efavirenz?
How does Comparator: Placebo to efavirenz work?
What is Comparator: Placebo to efavirenz used for?
Who makes Comparator: Placebo to efavirenz?
What drug class is Comparator: Placebo to efavirenz in?
What development phase is Comparator: Placebo to efavirenz in?
What are the side effects of Comparator: Placebo to efavirenz?
What does Comparator: Placebo to efavirenz target?
Related
- Drug class: All Non-nucleoside reverse transcriptase inhibitor (NNRTI) drugs
- Target: All drugs targeting HIV reverse transcriptase
- Manufacturer: Merck Sharp & Dohme LLC — full pipeline
- Therapeutic area: All drugs in Infectious Disease / Virology
- Indication: Drugs for HIV-1 infection (as part of combination antiretroviral therapy)
- Compare: Comparator: Placebo to efavirenz vs similar drugs
- Pricing: Comparator: Placebo to efavirenz cost, discount & access